February 2023 in “PLOS ONE” Caizhixuan hair tonic helps treat hair loss by promoting hair growth and improving hair follicles.
August 2003 in “药物不良反应杂志” Combining finasteride and terazosin can cause severe allergic reactions.
3 citations
,
June 1999 in “The Prostate” Finasteride reduces PSA levels, terazosin doesn't affect them, and tracking prostate cancer in patients taking finasteride could be difficult.
2 citations
,
April 2023 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.
July 2024 in “Open Repository of the University of Porto (University of Porto)” Dutasteride is more effective than finasteride for hair growth, and pregabalin effectively treats neuropathic pain.
2 citations
,
April 2017 in “Journal of Investigative Dermatology” Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.
January 2004 in “Actualidad en farmacología y terapéutica” Combining doxazosin and finasteride is more effective for managing benign prostatic hyperplasia than using either drug alone.
November 2025 in “Mendeley Data” Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.
16 citations
,
July 2017 in “Rheumatology and Therapy” Tofacitinib, a medication for arthritis, showed potential for treating severe hair loss in a small Brazilian case series, but more research is needed.
42 citations
,
July 2021 in “Frontiers in Medicine” Proxalutamide significantly lowered hospital admissions for male COVID-19 patients compared to a placebo.
25 citations
,
October 2008 in “Chromatographia” A fast and accurate method was developed to measure alfuzosin and dutasteride in human plasma.
February 2026 in “Mendeley Data” Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.
1 citations
,
December 2023 in “Journal of the European Academy of Dermatology and Venereology” 5 citations
,
July 2024 in “Archives of Dermatological Research”
41 citations
,
June 1999 in “The Prostate” Finasteride reduces PSA levels, terazosin doesn't affect them, and tracking prostate cancer in patients taking finasteride could be difficult.
December 2025 in “Clinical & Experimental Dermatology and Therapies” Cosmerna ARI effectively reduces hair loss and increases hair density in Europeans with androgenetic alopecia.
Some dermatologists in Saudi Arabia prescribe Tofacitinib for hair loss, but many don't due to its unavailability and safety concerns.
9 citations
,
October 2021 in “International Journal of Dermatology” Tofacitinib is effective and safe for treating severe hair loss in a Saudi population.
June 2020 in “Dermatologic therapy” Using Janus kinase inhibitors (JAKi) in COVID-19 treatment requires careful consideration due to their immunosuppressive effects.
3 citations
,
April 2003 in “BJUI” Doxazosin alone or combined with finasteride improves prostate symptoms better than finasteride alone, without extra benefits.
7 citations
,
March 2011 in “Expert Opinion on Drug Safety” Exemestane is effective and safe for treating certain breast cancers, with mild side effects, but needs more research on long-term effects.
3 citations
,
August 2020 in “Case Reports in Dermatology” Tofacitinib treatment significantly improved a patient's psoriasis, psoriatic arthritis, and alopecia universalis.
July 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Biochanin A from soy is a promising and safe candidate for treating hair loss.
March 2005 in “The Nurse Practitioner” June 2026 in “British Journal of Dermatology” Amivantamab treatment often causes skin issues that can affect quality of life and treatment continuation.
November 2008 in “Journal of Generic Medicines” The document updates on EU legal changes, including pharmaceutical patents, class actions in Italy, and various drug-related rulings.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is generally safe for alopecia areata patients over 72 months.
5 citations
,
October 2024 in “Reumatismo” Upadacitinib significantly improved alopecia universalis and psoriatic arthritis in a patient.
May 2024 in “Reactions weekly”
5 citations
,
July 2021 in “bioRxiv (Cold Spring Harbor Laboratory)” Completing a 14-day proxalutamide treatment significantly lowers death rates in hospitalized COVID-19 patients.